What's hot

View all perspectives
      #EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Mul

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Multicentre study showed the protection gained from mortality, irreversible organ damage accrual and flare was no different btw the two targets @RheumNow #EULARBEST https://t.co/GbP25tTmX8
      #EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials?

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials? Deep machine learning identified distinct classes of ANA-RMD with distinct phenotypes & predicted long-term outcomes better than the legacy diagnoses @RheumNow https://t.co/W2hmmj0v8Y
      #EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus s

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
      #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts wi

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
      #EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive thera

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
      New targets and new treatments in #Sjogren’s disease:
      Long term outcomes of repeat cycles of RTX
      #EULAR2024
      CB https

      Annals of the Rheumatic Diseases ARD_BMJ

      1 year 3 months ago
      New targets and new treatments in #Sjogren’s disease: Long term outcomes of repeat cycles of RTX #EULAR2024 CB https://t.co/6fL3e33i8N
      STAR responder may be the way to go! Less placebo effect than CREST.
      Better in patients with low systemic activity. htt

      Bella Mehta bella_mehta

      1 year 3 months ago
      STAR responder may be the way to go! Less placebo effect than CREST. Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
      A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
      New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compare

      Annals of the Rheumatic Diseases ARD_BMJ

      1 year 3 months ago
      New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz
      Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our famil

      Rheumatology Nurses RNSociety

      1 year 3 months ago
      Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our families and loved ones every day! Take a moment to express your gratitude for their care and hard work. #CareerNurseAssistantsDay https://t.co/Mijr820gnE
      40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn

      Vasco C Romao romaovc

      1 year 3 months ago
      40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn
      predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/

      Peter Nash drpnash

      1 year 3 months ago
      predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/K4J6eQV0zh
      #EULAR2024

      21-24% of #APS patients have #metabolic syndrome

      Also ⬆️ rates if atherosclerotic plaque progression

      Dr Gurdeep S Dulay gurdeep_dulay

      1 year 3 months ago
      #EULAR2024 21-24% of #APS patients have #metabolic syndrome Also ⬆️ rates if atherosclerotic plaque progression in pts with #AntiPhospholipidSyndrome #CVD #IHD #ASCVD By @MariaTektonidou https://t.co/EZsxJE7YJa
      Fantastic presentation from @MiaRodziewicz using BILAG-BR data:

      ⭐️NPSLE had higher damage / disease activity
      ⭐?

      Sarah Dyball sarahdyball1

      1 year 3 months ago
      Fantastic presentation from @MiaRodziewicz using BILAG-BR data: ⭐️NPSLE had higher damage / disease activity ⭐️ NPSLE more likely to have APS ab ⭐️ RTX appears effective in NPSLE (no trials) https://t.co/25984cORj0
      Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with gre

      Anne Troldborg TroldborgAnne

      1 year 3 months ago
      Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with great response. ⁦@LUPUSDK⁩ ⁦@LupusEurope⁩ https://t.co/2C64ECzq83

      Podcasts

      • EULAR 2024 SLE Topic Panel
      • EULAR 2024 Psoriatic Arthritis Topic Panel
      • EULAR 2024 Rheumatology Roundup

      Catch up on Conference Podcasts

      ×